Bioequivalence and Bioavailability Forum 21:28 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

What's the problem? [Regulatives / Guidelines]

posted by kumarnaidu - Mumbai, India, 2017-07-11 14:43  - Posting: # 17533
Views: 13,480

Hi all,
Recently we did pilot and pivotal (Partial reference replicate) studies for WHO and we got high variability (CV=32%). In the USFDA product specific guidance they have suggested 2x2 crossover design for this drug. Based on our prior experience can we perform reference replicate study or need to go as per guidance?:confused:

Kumar Naidu

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,934 posts in 4,039 threads, 1,287 registered users;
online 8 (0 registered, 8 guests [including 6 identified bots]).

There are no such things as applied sciences,
only applications of science.    Louis Pasteur

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed